Supplementary Figures – PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer
|
Supplementary Figure S1. PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer Flow diagram showing inclusion and exclusion of studies and trial reference list
Supplementary Figure S2. PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer Impact of PD-L1 expression on progression-free survival. Forest plots display the progression-free survival (PFS) hazard ratios and 95% confidence intervals for the pairwise comparisons of PD-L1 high versus negative (A), low versus negative (B) and high versus low (C) in patients treated with platinum-doublet chemotherapy and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). The diamond represents the pooled overall effect size.
Supplementary Figure S3A-B. PD-L1 Expression as a Prognostic Marker in Patients treated with Chemotherapy for Metastatic Non-Small Cell Lung Cancer Impact of PD-L1 expression on overall survival with the exclusion of IMPOWER150 trial and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). Forest plots S3A display the overall survival (OS) hazard ratios and 95% confidence intervals for the pairwise comparisons of PD-L1 high versus negative (A), low versus negative (B) and high versus low (C) in patients treated with platinum-doublet chemotherapy and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). The diamond represents the pooled overall effect size. Forest plots S3B display the objective response rate (ORR) odds ratios and 95% confidence intervals for the pairwise comparisons of PD-L1 high versus negative (A), low versus negative (B) and high versus low (C) in patients treated with platinum-doublet chemotherapy and stratified by PD-L1 assay (Dako 22C3/28-8 versus Ventana SP142). The diamond represents the pooled overall effect size. |
